CN108785649B - Composition for controlling weight of pressure type obesity - Google Patents

Composition for controlling weight of pressure type obesity Download PDF

Info

Publication number
CN108785649B
CN108785649B CN201810408598.6A CN201810408598A CN108785649B CN 108785649 B CN108785649 B CN 108785649B CN 201810408598 A CN201810408598 A CN 201810408598A CN 108785649 B CN108785649 B CN 108785649B
Authority
CN
China
Prior art keywords
weight
composition
sleep
tea
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810408598.6A
Other languages
Chinese (zh)
Other versions
CN108785649A (en
Inventor
熊晓云
任武贤
雷凤爱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yabao Pharmaceutical Group Corp
Original Assignee
Shanxi Yabao Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi Yabao Pharmaceutical Group Corp filed Critical Shanxi Yabao Pharmaceutical Group Corp
Publication of CN108785649A publication Critical patent/CN108785649A/en
Application granted granted Critical
Publication of CN108785649B publication Critical patent/CN108785649B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses a composition for controlling the weight of pressure type obesity, which is prepared by compounding tea flowers and casein hydrolysate according to a certain proportion. The composition has a remarkable effect on relieving the stress obesity compared with a single component through compatibility, and the composition synergistically controls the weight of the stress obesity and has a remarkable effect.

Description

Composition for controlling weight of pressure type obesity
Technical Field
The present invention relates to a composition for weight control of stress type obesity.
Background
With the rapid development of economic society and the acceleration of learning, working and living rhythm, people find that the statue which is supposed to be pride is gradually deformed in fierce competition and fighting, and the obesity becomes a disease which is popular all over the world, in particular to the obesity of children.
It has been shown that once a person is under anxiety and stress, the person often increases his diet to relieve stress, and at the same time, the body secretes stress-coping hormones, which convert heat into fat that is stored in the body, and if the person is under anxiety and stress for a long time, the stored fat is gradually increased. In addition, various behaviors of a human are the result of actions of various hormones and substances, hormone secretion can affect psychological changes, the hormone secretion in the body is necessarily disturbed when the human is in an anxiety state, and the adrenal medulla hormone can reduce glycogenolysis, lipolysis, thermogenesis and glucose utilization. At present, the obese people caused by anxiety tend to rise year by year. The clinical treatment method for obesity is mainly diet and exercise therapy; but there are mainly 'one-time' ways of controlling carbohydrate, fat and protein intake and blindly adopting non-individualized treatment of weight-reducing drugs.
In addition, sleep quality is also a major cause of obesity. There is increasing evidence that sleep disorders are associated with obesity, and inadequate sleep time, biological clock disorders, sleep persistence, impaired daytime function are common in children and adolescents, mainly due to an excessive learning burden, cultural levels of parents, home environment, self-mutism, and anxiety. Anxiety insomnia not only affects the mental state of people, but also brings great pain to patients. Anxiety aggravates the mental stress of people, mostly in an excited state, and long-time excitation causes excitation-inhibition coupling disorder, so that many people often have insomnia, dreaminess, tiredness, hypodynamia, absentmindedness and palpitation, and the symptoms are currently medically diagnosed as 'mental asthenia', 'sinus arrhythmia' or generically called 'insomnia'. The survey results show that about 45.4 percent of people in China have insomnia with different degrees. The incidence of poor sleep quality tends to rise with age, with 15% -38% of undergraduate sleep disorders and 39.5% of middle aged people having poor or poor sleep quality. Due to insufficient sleep and poor sleep quality, about 50% of people have lassitude in the daytime, 38.9% of people have limited activities in the daytime, and 27.7% of people have poor mood. However, such serious sleep disorders have not attracted attention. According to the investigation, people who have visited medical services due to sleep disorder only account for 1/4, and people of about 1/2 only listen to them and do not take any measures. People with poor sleep conditions in China are increasing continuously, health-care food with the function of improving sleep is favored by suitable people, and people pay more and more attention to health along with the improvement of national living standard and cultural level. At present, sedation, hypnosis and vegetative nerve function regulation are applied in treatment, and diazepam, oryzanol and vitamin B1 are preferred, chlorpromazine, rotundine and the like are used for symptomatic treatment in severe cases, aiming at regulating excitation-inhibition coupling, but the effect is not satisfactory. After patients take the medicines, great dependence is generated, i.e. addiction is formed, even dosage is increased, otherwise, not only symptoms are not improved, but also insomnia is more serious. Because this therapy can only treat the secondary aspect of the disease, but not the primary aspect. The long-term taking of the medicine can also cause the decrease of granulocytes, even damage the kidney function and cause sleepiness after waking. The traditional Chinese medicines for treating the diseases are blood-nourishing and nerve-soothing tablets, semen boitae heart-nourishing pills, magnetic pills, spleen-invigorating pills, Tianwang heart-tonifying pills, sleeping peace (named Gaowangyuansan), ginseng tonic pills, Naolejing, Xiaoyao pills and the like, and the medicines are prepared according to the principle of nourishing heart yin, enriching blood and soothing nerves. Compared with the prior art, the medicine has low toxic and side effects, but can only be effective on partial mild patients, but can not completely cure most severe patients and only improve symptoms. At present, no ideal medicine for the diseases exists, more than four hundred Chinese health foods which are approved by China to improve the sleep function are available, the effect of the health foods on improving the sleep quality is not very obvious, people with poor sleep conditions in China are in a rising trend, and the products cannot meet the market demand.
At present, products for controlling the weight of the pressure type obesity do not exist in the market, most patients are treated by adopting a combined medicine mode, and the combined medicine has more incompatibility; the health food is used for improving a small number of sub-healthy people, but the effect is not very remarkable, so that the development of a product for the weight control of the stress obesity is necessary.
The invention unexpectedly discovers that the combined application of the tea flower and the casein hydrolysate has a synergistic effect, and the phenomenon of weight imbalance of the pressure type obesity is greatly improved.
Disclosure of Invention
The invention discloses a composition which has a synergistic effect and is used for controlling the weight of pressure type obesity.
The active ingredients of the composition comprise tea flower and casein hydrolysate, wherein the weight parts of the tea flower are 10-1, and the weight parts of the casein hydrolysate are 1-10; preferably, the weight parts of the tea flower and the casein hydrolysate are 5-1; more preferably 3 parts by weight of tea flower and 1 part by weight of casein hydrolysate.
The Tea flower (Tea blossom) is a flower of Camellia sinensis (L.) o.kuntze in the genus Camellia of the family theaceae, is a reputation of "placenta of safe plants" and "essence on Tea trees", is rich in various beneficial components and active substances such as protein, Tea polyphenol, Tea polysaccharide, Tea saponin, flavonoid, amino acid, caffeine and the like, is widely planted in the central and south provinces of china in the origin place of china, and is approved as a new food raw material by the Ministry of health in 2013, 1 month and 4 days (No. 1 of Ministry of health, No. 2013). Researches show that the tea flower extract has the function of weight control, and the composition containing the white kidney bean extract, the tea flower extract, the green tea extract and the inulin, which is provided by the patent CN 105685995 'a weight-losing composition', has obvious effect on weight reduction and can play a weight-losing role for obese people; the patent CN 106359734 a, "sugar-free tea beverage with weight-reducing function and preparation method thereof" provides a beverage comprising tea components, tea flower extract and prickly pear powder, which has the function of weight-reducing and assisting weight management; in addition, tea flower has gastric mucosa protecting effect.
The casein hydrolysate is an all natural milk protein hydrolysate, which contains bioactive decapeptide, and has relaxing effect; the material is certified by common foods of a plurality of countries, can be widely used as a common food raw material, has no toxicity, no side effect and no addiction, and has literature data showing that various symptoms caused by anxiety and stress, including insomnia, overeating and the like, can be effectively relieved. In patent CN 104719918A, "a composition for improving sleep quality and its preparation" mentioned that the composition includes gamma-aminobutyric acid and casein hydrolysate, and after the two are used in combination, the sleep time induced by pentobarbital sodium can be significantly prolonged, the sleep latency induced by pentobarbital sodium can be shortened, and the effect of improving sleep is significant.
The preparation method of the composition comprises the following steps: sieving tea flower and casein hydrolysate respectively, weighing at a certain ratio, placing in a mixer, mixing, sieving, and packaging.
The composition can be mixed with pharmaceutic adjuvants and prepared into oral medicaments, health-care foods, formula foods for special medical purposes and functional nutritional foods according to the conventional technology of pharmaceutics; it can be any one of powder, granule, tablet, hard capsule, oral liquid, and suspension.
The invention has the following advantages:
1. the invention selects high-quality food raw materials, adopts the synergistic effect of the two raw materials to prevent the weight control of the pressure type obesity, and has no toxicity, no side effect and no addiction.
2. The composition provided by the invention develops a composition for controlling the weight of the stress type obesity from the perspective of a fattening factor-stress, and the application range is wide.
3. Through short-term animal experiments and clinical observation, the weight control method has a good effect on the weight control of the pressure type obesity.
Detailed Description
EXAMPLE 1 preparation of a composition according to the invention
1) Sources of materials
Tea flower (API company, product batch: 140618)
Casein hydrolysate (Ingredia, product batch: U15465)
2) Preparation conditions
The environmental humidity is controlled below 40%, and the temperature is 18-25 deg.C
3) Preparation process
Respectively sieving tea flower and casein hydrolysate, weighing samples according to the proportion shown in table 1, placing the samples in a mixer, mixing for 5-20 minutes at a rotating speed of 20-30 revolutions per minute, sieving the mixed materials, and packaging. The water content is less than 5 percent, and the microbial limit meets the regulation.
TABLE 1 materials and compounding ratios contained in the compositions of the invention
Figure BDA0001644792550000031
Figure BDA0001644792550000041
"tea" represents the material tea flowers; "Casein" refers to casein hydrolysate.
EXAMPLE 2 preparation of various dosage forms of the compositions of the invention
Powder preparation: the environmental humidity is controlled to be below 40%, the temperature is controlled to be 18-25 ℃, the raw and auxiliary materials are crushed, sieved and weighed, a proper amount of auxiliary materials capable of being accepted by the medicinal materials, the composition of the embodiment 1, other compound raw materials and a proper amount of auxiliary materials capable of being accepted by the medicinal materials are alternately added into a mixer, the mixing time is 5-30 min, the rotating speed is 20-30 r/min, the mixed powder is sieved by a 20-40 mesh sieve, and the mixture is quantitatively packaged. The water content is less than 5 percent, and the microbial limit meets the regulation.
Granules: the composition of the embodiment 1, other compound raw materials and a proper amount of auxiliary materials are taken. Mixing, spraying, granulating, drying, sieving, grading, and packaging.
And (3) tablet preparation: further tabletting the obtained granule, drying, and making into tablet.
Hard capsule preparation: encapsulating the obtained granule to obtain capsule.
Oral liquid: taking the composition of the embodiment 1, other water-soluble compound raw materials and a proper amount of auxiliary materials, stirring and dissolving in water, quantitatively filling and sterilizing.
Suspension: taking the composition of the embodiment 1, other compound raw materials, an appropriate amount of auxiliary materials such as an emulsifier and the like, stirring and dissolving in water, shearing at a high speed, homogenizing at a high pressure, quantitatively filling, and sterilizing.
Example 3 animal experiments on the weight control of stress obesity with the composition of the present invention
Experimental animals: healthy male SD mice, 6-8 weeks (body weight: 20 ± 2g), were provided by the fourth department of military medical university test animal center, and the certificates: SCXK (military) 2002-.
The experimental method comprises the following steps: experimental animals three days after quarantine under laboratory conditions, 120 mice were randomly divided into 10 experimental groups of 12 animals each, and gavage was performed daily.
The experimental time was 4 weeks.
The protocol is shown in the table:
TABLE 2 test protocol
Figure BDA0001644792550000051
During the experiment, the weight of the sample is weighed, and 50mL of sample liquid is prepared by purified water and is used for animal gavage. The negative control group 1 was given a positive diet without any stimulation, and the other groups received unpredictable stress stimulation for 1 month. The specific method of each stress is:
(1) tail clamping: putting the mouse into a fixed cage, exposing the tail, clamping the tail with a hemostatic clamp (the mouse does not feel too much force to give out howling), and keeping for 1min (2) for wet breeding: at 8 am, 100ml of water was added to the cage until eight o' clock the day next and the cage was replaced. (3) The day and night are reversed: the mouse is placed in the dark box at 8 points in the morning, and the illuminating lamp is turned on at 8 points in the evening till 8 points in the morning next day. The body weight of the mice was tested before and after the experiment.
After the test is finished and the test samples are given to the control group and the test group, the animals in each group are injected with 50mg/kg BW of sodium pentobarbital in the abdominal cavity, the injection amount is 0.2mL/20g BW, and the weight change of the mice and whether the sleep time induced by the sodium pentobarbital is prolonged or not after the samples are given are observed by taking the disappearance of positive reflection as an index.
Data processing: analysis of variance and X with the SPSS17.0 software package2And (6) checking.
And (3) test results: the weight change and the test for prolonging the sleep time of the sodium pentobarbital are shown in the table.
TABLE 3 Effect of groups on weight change and sleep time of pentobarbital sodium induced mice
Figure BDA0001644792550000052
Figure BDA0001644792550000053
Figure BDA0001644792550000061
Note: indicates significant difference (p < 0.05) and indicates extremely significant difference (p < 0.01) compared with the negative control group 1;
effect of tea flowers and casein hydrolysate on the sleep time of pentobarbital sodium-induced mice after combined use: the sleep time of animals in each test group is prolonged, the sleep time of the fourth test group and the sleep time of the fifth test group have significant difference (P is less than 0.05) compared with that of a negative control group, the sleep time of the third test group has significant difference (P is less than 0.01) compared with that of the negative control group, and the sleep time of the first test group and the sleep time of the second test group have no statistical significance;
the test groups reduce the sample amount of tea flower and casein hydrolysate, but the sleep time of the sodium pentobarbital in the third test group is longer than that of the first control group and is equivalent to that of the second control group and the positive control group, which shows that the combined use of the tea flower and the casein hydrolysate can still achieve better sleep effect under the condition of reducing the sample amount.
Effect of tea flowers on weight change after combined use with casein hydrolysate: the change of the animal body weight of each experimental group is reduced, compared with the negative control group 1, the change of the body weight of the third experimental group is extremely obvious (P is less than 0.01), the change of the body weight of the first and second experimental groups is obvious (P is less than 0.05), the change of the body weight of the negative control group 2 is obvious (P is less than 0.01), and the change of the body weight of the first control group is obvious (P is less than 0.05), which suggests that the amount of the tea tree flower is reduced after the tea tree flower is combined with the casein hydrolysate, but a certain weight control effect can be achieved.
Example 4 human experiment of the composition of the present invention for weight control of stress type obesity
On the basis of the above animal experiments, the third test group (tea flower 216mg/(kg.d), casein hydrolysate 72mg/(kg.d)) was selected, and the 1/10 dose was estimated as the human dose (tea flower 240mg/(70kg.d), casein hydrolysate 80mg/(70 kg.d)). Is administered 1 time a day.
And (3) inclusion standard: body mass index (BMI value) greater than 23; the patients complain of insomnia (difficult sleep onset (sleep onset time >30min)), sleep maintenance disorder (night wakefulness times > 2), early awakening, sleep quality reduction and total sleep time reduction (1 item (usually < 6 h)), social function impairment in daytime (symptoms of dizziness, sleepiness, fatigue, inattention, hypomnesia, mood fluctuation, interest reduction and the like) and insomnia lasting for more than 1 month.
The selected population: of the 80 enrolled groups, 29 were males and 51 were females, and were voluntarily enrolled in the trial. The selected population was randomly and equally divided into 4 groups of 20 individuals, each group being a control group, a tea flower group (taking tea flower 240mg/(70kg. d)), a casein group (casein hydrolysate 80mg/(70kg. d), a composition group (tea flower 240mg/(70kg. d), casein hydrolysate 80mg/(70kg. d)).
The test period is 30d, the weight, the sleep quality, the sleep persistence, the sleep disorder and other parameters of the patient are recorded every week during the test period, and the Pittsburgh sleep quality index (PQSI) is adopted to evaluate the sleep quality of the selected patient.
1. Influence on body weight
TABLE 4 Effect on body weight
Group of n Weight loss (kg)
Normal control group 20 0.8±0.6
Tea flower group 20 5.8±0.7*
Casein group 20 2.1±0.6
Composition set 20 7.5±1.0**
Note: marked difference (p < 0.05) and extremely marked difference (p < 0.01) compared with the normal control group
As can be seen from the above table, the body weight of the tea flower group, the casein group and the composition group were reduced to different degrees compared with the control group, wherein the composition group reached a very significant level (p < 0.01), the tea flower group was significantly reduced (p < 0.05) and the casein group had no statistical significance.
2. Effects on sleep state
TABLE 5 changes in sleep State before and after the experiment
Figure BDA0001644792550000071
Figure BDA0001644792550000081
Sleep states are mainly judged from subjective feelings.
After one month experiment, the sleep condition of the group taking the composition is obviously improved, the total sleep quality reject ratio is reduced from 92% to 12%, the sleep persistence reject ratio is reduced from 86% to 15%, the sleep efficiency reject ratio is reduced from 88% to 16%, and the sleep disturbance reject ratio is reduced from 78% to 5%; the functional disability rate in the daytime is reduced from 90% to 15%.
3. Comparison of PSQI factor scores before and after testing
TABLE 6 comparison of PSQI factor scores before and after experiment
Figure BDA0001644792550000082
Figure BDA0001644792550000091
Note: marked difference (p < 0.05) and extremely marked difference (p < 0.01) compared with the control group
As can be seen from the table above, the PSQI factor scores of the tea flower group, the casein group and the composition group are all reduced after the experiment, compared with the control group, the casein group is obviously reduced (p is less than 0.05), the composition group is obviously reduced (p is less than 0.01), and the sleep effect and the sleep quality of the experimental patient are obviously improved after the composition is adopted.
The above-described embodiments are intended to illustrate the substance of the present invention, but are not intended to limit the scope of the present invention. It will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the true spirit and scope of the invention.

Claims (4)

1. Use of a composition of tea flowers and casein hydrolysate for the preparation of a product for weight control of stress obesity, said composition comprising 10-1 parts by weight of tea flowers and 1-10 parts by weight of casein hydrolysate.
2. The use as claimed in claim 1, wherein the composition comprises 5-1 parts by weight of tea flower and 1-5 parts by weight of casein hydrolysate.
3. The use as claimed in claim 2, which comprises 3 parts by weight of tea flowers and 1 part by weight of casein hydrolysate.
4. The use according to any one of claims 1 to 3, wherein the composition is prepared into oral medicaments, health-care foods or formula foods for special medical use according to the conventional technology of pharmaceutical science; it is in the form of powder, granule, tablet, hard capsule, oral liquid, or suspension.
CN201810408598.6A 2017-05-04 2018-04-28 Composition for controlling weight of pressure type obesity Active CN108785649B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710309094 2017-05-04
CN2017103090944 2017-05-04

Publications (2)

Publication Number Publication Date
CN108785649A CN108785649A (en) 2018-11-13
CN108785649B true CN108785649B (en) 2020-11-03

Family

ID=64093341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810408598.6A Active CN108785649B (en) 2017-05-04 2018-04-28 Composition for controlling weight of pressure type obesity

Country Status (1)

Country Link
CN (1) CN108785649B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105506046A (en) * 2016-01-15 2016-04-20 中国农业大学 Yak milk Qula based casein glucose-lowering lipid-lowering peptide as well as preparation method and application thereof
CN106798060A (en) * 2016-12-15 2017-06-06 李作丹 A kind of after fermentation Tea Flower jasmine tea and its preparation technology based on white tea technique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105506046A (en) * 2016-01-15 2016-04-20 中国农业大学 Yak milk Qula based casein glucose-lowering lipid-lowering peptide as well as preparation method and application thereof
CN106798060A (en) * 2016-12-15 2017-06-06 李作丹 A kind of after fermentation Tea Flower jasmine tea and its preparation technology based on white tea technique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
凌泽杰等.茶树花对大鼠肥胖病和高脂血症预防作用研究.《中国食品学报》.2011, *
黄远英等.酪蛋白水解物与γ-氨基丁酸复配制剂改善睡眠功能的研究.《食品安全质量检测学报》.2016, *

Also Published As

Publication number Publication date
CN108785649A (en) 2018-11-13

Similar Documents

Publication Publication Date Title
Bartram Bartram's encyclopedia of herbal medicine
JP2009502958A (en) How to treat or manage stress
CN108543020A (en) A kind of medicinal health-care preparation and preparation method thereof for improving sleep
US20230125425A1 (en) Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof
CN105230970B (en) A kind of poultry fodder additive and preparation method thereof
RU2333677C2 (en) Dietary supplement
KR20180026190A (en) A composition for improving, preventing and treating pulmonary disease comprising herb extract
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN108785649B (en) Composition for controlling weight of pressure type obesity
WO2020089831A1 (en) Phyto-therapyc compositions useful to improve the quality of sleep and in the treatment of insonnia, anxiety and depression
RU2174003C1 (en) Pharmaceutical curative composition, method of curative and curative- prophylactic use of thereof
KR101642176B1 (en) Composition for enhancing growth and reinforcing immunity
KR20200087606A (en) Compositions for Improving Memory Power and Learning Ability, and Relaxing stress
CN112546120B (en) Product containing folic acid for relieving anxiety
CN107789562A (en) A kind of composition of integration of drinking and medicinal herbs is preparing the application in improving sleep-disorder or improving Memory Impairment medicine or health food
CN107050143A (en) It is a kind of that there is the formula for improving sleep effect, composition and preparation method thereof
CN104548020B (en) A kind of purposes of pharmaceutical composition in treatment senile dementia is prepared
US20190216877A1 (en) Composition comprising pollen and/or pistil extracts, preparation process and associated uses
CN106177634A (en) A kind of weight-reducing compound preparation and preparation method thereof
KR101769972B1 (en) A composition for improving, preventing and treating pulmonary disease comprising herb extract
US6106839A (en) Ayurvedic composition for the treatment of disorders of the nervous system including Parkinson&#39;s disease
KR20010009653A (en) Composition for treating sexual dysfunction
KR20140124172A (en) Cosmetic Compositions for Skin improvement
CN102885956B (en) A kind of sleeping Chinese medicine composition and preparation method thereof
AU2020102056A4 (en) Calcium supplemented gel candy and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant